Aqst stock forecast for AQST stock forecast

For AQST stock forecast, a key watchpoint is the upcoming FDA meeting on its oral film drug delivery platform. Positive feedback could drive speculative buying and re-rate the shares in the near term. It hasn't been the best quarter for Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders, since the share price has fallen 25% in that time. While that might be a setback, it doesn't negate the nice returns received over the last twelve months. In that time we've seen the stock easily surpass the market return, with a gain of 88%. The Anaphylm Sublingual Film is being developed as a non-invasive oral epinephrine product candidate. AQST stock forecast remains favorable as the company advances AQST-109 into Phase 3 trials. Market watchers see catalyst-driven volatility ahead, making it a potential swing trade within the biotech basket.